Literature DB >> 15721399

Endometrial cancer: can nodal status be predicted with curettage?

Andrea Mariani1, Thomas J Sebo, Jerry A Katzmann, Patrick C Roche, Gary L Keeney, Timothy G Lesnick, Karl C Podratz.   

Abstract

OBJECTIVE: To determine whether histologic or molecular markers assessed in pretreatment curettage specimens predict nodal metastasis in endometrial cancer.
METHODS: Phenotypic and molecular variables (ploidy, proliferating cell nuclear antigen, MIB-1, p53, HER-2/neu, and bcl-2) were analyzed in preoperative specimens from 82 patients with endometrial cancer who had lymph nodes dissected. These 82 patients had been selected from a total population of 283 patients with endometrial cancer, using a case-cohort design. Weighted logistic regressions were then used to determine significant predictors of positive lymph nodes, and results were estimated for the total population of 283 patients.
RESULTS: Of the overall population, 12% of patients were estimated to have positive lymph nodes. Histologic subtype, p53, and bcl-2 each were significantly correlated (P <0.05) with lymph node status. With application of stepwise logistic regression, p53 was the only independent predictor of lymph node status. In addition, a statistical model predictive of positive lymph nodes was generated which incorporated the risk factors p53, bcl-2, and histologic subtype.
CONCLUSION: In pretreatment curettage specimens, the presence of unfavorable levels of p53 or bcl-2 or of nonendometrioid histologic features, or combinations of those, significantly predicted lymph node status, thus facilitating the preoperative identification of patients at risk of lymph node metastases.

Entities:  

Mesh:

Year:  2005        PMID: 15721399     DOI: 10.1016/j.ygyno.2004.11.030

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

Review 1.  Current status of molecular biomarkers in endometrial cancer.

Authors:  H M J Werner; H B Salvesen
Journal:  Curr Oncol Rep       Date:  2014-09       Impact factor: 5.075

2.  DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer.

Authors:  T S Njølstad; J Trovik; T S Hveem; M L Kjæreng; W Kildal; M Pradhan; J Marcickiewicz; S Tingulstad; A C Staff; H K Haugland; R Eraker; K Oddenes; J A Rokne; J Tjugum; M S Lode; F Amant; H M Werner; H B Salvesen; H E Danielsen
Journal:  Br J Cancer       Date:  2015-04-21       Impact factor: 7.640

3.  The sL1CAM in sera of patients with endometrial and ovarian cancers.

Authors:  Michał Wojciechowski; Ewa Głowacka; Miłosz Wilczyński; Anna Pękala-Wojciechowska; Andrzej Malinowski
Journal:  Arch Gynecol Obstet       Date:  2016-11-10       Impact factor: 2.344

4.  Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study.

Authors:  Yovanni Casablanca; Guisong Wang; Heather A Lankes; Chunqiao Tian; Nicholas W Bateman; Caela R Miller; Nicole P Chappell; Laura J Havrilesky; Amy Hooks Wallace; Nilsa C Ramirez; David S Miller; Julie Oliver; Dave Mitchell; Tracy Litzi; Brian E Blanton; William J Lowery; John I Risinger; Chad A Hamilton; Neil T Phippen; Thomas P Conrads; David Mutch; Katherine Moxley; Roger B Lee; Floor Backes; Michael J Birrer; Kathleen M Darcy; George Larry Maxwell
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.